Find Your Funding Opportunity
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
Service
|
Source |
Final Application Due Date |
Funding Available
|
Match Required
|
|---|---|---|---|---|
| Health Care |
Federal
HHS |
08-18-2026 | N/A | No Match Required |
-
Service
-
Source
-
Final Application Due Date
-
Funding Available
-
Match Required
Status
- Opportunity Type Discretionary
-
CFDA
93.121 -- Oral Diseases and Disorders Research
93.213 -- Research and Training in Complementary and Integrative Health
93.242 -- Mental Health Research Grants
93.273 -- Alcohol Research Programs
93.279 -- Drug Abuse and Addiction Research Programs
93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders
93.865 -- Child Health and Human Development Extramural Research
93.866 -- Aging Research
93.867 -- Vision Research
Description
Reissue of PAR-18-546. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.
Eligibility
- IHE
- Local Government
- Non-Profit
- Other
- State Government
- Tribal Government
Additional Eligibility Information
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Key Date(s)
- November 02, 2023: Last Updated Date
- November 02, 2023: Posted Date
- August 18, 2026: Current Closing Date for Applications
- August 18, 2026: Application Due Date
- September 23, 2026: Application Archive Date
Contact Information
NIH Grants Information
grantsinfo@nih.gov